Eliaz Therapeutics
Company profile on P2PMarketData. Eliaz Therapeutics is a medical devices company based in Santa Rosa, CA, founded in 2015. It is raising on DealMaker now.
Eliaz Therapeutics develops medical devices designed to remove Galectin-3 protein from the blood to address sepsis progression. The company's primary product, XGAL-3®, has received FDA Breakthrough Device Designation. Based in Santa Rosa, California, Eliaz Therapeutics holds multiple patents across several countries and is advancing toward clinical trials for its sepsis treatment technology.
Frequently asked questions about Eliaz Therapeutics
How much funding has Eliaz Therapeutics raised?
Eliaz Therapeutics has raised $3.2M through crowdfunding across 3 rounds tracked by P2PMarketData, from 1,806 investors.
What is Eliaz Therapeutics' valuation?
Eliaz Therapeutics had an indicative valuation of $59.4M in its 2026 funding round.
What is Eliaz Therapeutics' revenue?
Eliaz Therapeutics reported revenue of $332.2K for fiscal year 2025.
Is Eliaz Therapeutics profitable?
No. Eliaz Therapeutics reported a net loss of $1.7M for fiscal year 2025.
How many employees does Eliaz Therapeutics have?
Eliaz Therapeutics reported 2 employees for fiscal year 2025.
Can I invest in Eliaz Therapeutics?
Yes. Eliaz Therapeutics has an open crowdfunding deal on DealMaker.
When was Eliaz Therapeutics founded?
Eliaz Therapeutics was founded in September 2015.
Where is Eliaz Therapeutics based?
Eliaz Therapeutics is headquartered in Santa Rosa, California, United States, and is incorporated in Delaware, United States.
What industry is Eliaz Therapeutics in?
Eliaz Therapeutics operates in the Medical Devices industry within the Healthcare sector.